Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

Last updated: February 24, 2022
Sponsor: Kochi University
Overall Status: Active - Recruiting

Phase

2/3

Condition

Pancreatitis

Cancer/tumors

Pancreatic Cancer

Treatment

N/A

Clinical Study ID

NCT05268692
GSGnP
  • Ages 18-85
  • All Genders

Study Summary

The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.

Eligibility Criteria

Inclusion

Inclusion Criteria: elective pancreatectomy for pancreatic cancer

Exclusion

Exclusion Criteria: a previous cancer surgery a body weight loss of >10% during the 6 months before surgery thepresence of distant metastases seriously impaired function of vital organs because ofrespiratory, renal, or heart disease.

Study Design

Total Participants: 500
Study Start date:
January 01, 2019
Estimated Completion Date:
December 31, 2030

Study Description

gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel

Connect with a study center

  • Takehiro Okabayashi

    Kochi, 781-8555
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.